PSMA PET for the Staging and Management of Hepatocellular Carcinoma

Launched by MIAMI VA HEALTHCARE SYSTEM · Jun 5, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called F18-Piflufolastat (PSMA) PET/CT to see how well it works for diagnosing and managing liver cancer known as hepatocellular carcinoma (HCC). The researchers want to find out if using this advanced imaging method, along with traditional imaging tests, can give doctors better information about liver lesions and help them make more accurate decisions about treatment and care for patients with HCC.

To be eligible for the trial, participants must be adults over 18 years old who are new patients with HCC that falls into specific stages of the disease (BCLC B or C). However, people with certain health issues, like kidney problems or other active cancers, are not able to join. If you participate, you can expect to undergo additional imaging tests and help researchers understand how this new PET scan could improve the diagnosis and treatment of liver cancer. The trial is currently recruiting participants, and everyone is welcome, regardless of gender.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. adult patients age\>18 years from the VA medical system; 2. Treatment-naïve patients with HCC with BCLC B or C disease.
• Exclusion Criteria:
• • 1. Patients with renal dysfunction or contrast allergy that precludes contrast enhanced cross sectional imaging; 2. Patients with presence of active primary malignancy other than HCC and non-melanoma skin cancer in the past 3 years.